Development and Evaluation of SARS- CoV-2 RNA Polymerase Inhibitors

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$502,766.41
Funder
Canadian Institutes of Health Research (CIHR)
Principal Investigator
Pending
Research Location
Canada
Lead Research Institution
University of Alberta
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Subject
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2011, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we oppose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.

Publicationslinked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein.

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.